Heart scan guided choice of pacemaker type in non-ischemic cardiomyopathy with heart failure
Compares two pacing devices in adults with non-ischemic cardiomyopathy, sorted by heart scan risk.
Plain-language title generated from the registry record
Registry title: Magnetic Resonance Imaging Based Risk Stratification for Defibrillator Implantation in Heart Failure Patients Requiring Cardiac Resynchronisation Therapy
Key facts
- Where
- Madurai, IndiaSee the site
Where in India
- Velammal Medical College Hospital and Research InstituteMadurai, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Velammal Medical College Hospital and Research Institute
- Trial code
- NCT07791407
- Record updated
- 27 August 2026
- Original description
This randomized study aimed to compare the efficacy of LBBP without defibrillator vs biventricular pacing with defibrillator (BiV-ICD/CRT-D) in patients with LB-NICM and left ventricular ejection fraction (LVEF) ≤35% risk categorized by CMR imaging.Read full original descriptionShow less
Magnetic Resonance Imaging Based Risk Stratification for Defibrillator Implantation in Heart Failure Patients Requiring Cardiac Resynchronization Therapy (MADURAI CRT)
This randomized study aimed to compare the efficacy of LBBP without defibrillator vs biventricular pacing with defibrillator (BiV-ICD/CRT-D) in patients with LB-NICM and left ventricular ejection fraction (LVEF) ≤35% risk categorized by CMR imaging.
Inclusion: Patients with age ≥18 years; Typical left bundle branch block as defined by Strauss criteria with LVEF ≤35%; Heart failure symptoms despite guideline directed medical therapy (GDMT).
Exclusion: Patients with associated uncorrected congenital or valvular heart disease; Patients with contrast allergy; Patients with angiographic evidence of significant coronary artery disease requiring revascularisation. In patients with significant CAD, LVEF will be re-assessed 3 months after revascularisation to decide about CRT; Expected life-expectance of <12 months due to associated comorbidities; Baseline non-LBBB morphology; Renal dysfunction which limits the acquisition of CMR with contrast; Pregnant or lactating women; Patients who are unable to comply with study protocol.